A New Test Predicts Who Will Benefit Most from Weight-Loss Drugs

As popular as the new group of weight-loss drugs like Wegovy and Zepbound are, not everyone responds to them in the same way.

In a new presentation at the Digestive Disease Week conference in Washington, Mayo Clinic associate professor of medicine Dr. Andres Acosta reported that a genetic test he developed can identify which people are most likely to respond to semaglutide (Wegovy) and which are not.

The test, called MyPhenome, from a company Acosta co-founded called Phenomix...